Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from

and

Download Data

Compass Therapeutics Inc. Days in Inventory for the Trailing 12 Months (TTM) ending March 31, 2024

Compass Therapeutics Inc. Days in Inventory is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The days in inventory ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing 365 by the ratio of cost of revenue to the average of inventory and other current assets. This ratio indicates the efficiency of inventory management and the company's ability to convert inventory into sales within a specific period. A lower number of days in inventory is generally preferable.

NASDAQ: CMPX

Compass Therapeutics Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street, Boston, MA, United States, 02135
Employees	32
Sector	Healthcare
Industry	Biotechnology

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends